SG11201900181RA - Insulin analogs - Google Patents
Insulin analogsInfo
- Publication number
- SG11201900181RA SG11201900181RA SG11201900181RA SG11201900181RA SG11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- utah
- insulin analogs
- victoria
- salt lake
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 0 11101 HOE 3E1 0 0111111 0101110110M OE 11110 ill 011 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/014091 Al 25 January 2018 (25.01.2018) WIP0 I PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every C07K 14/62 (2006.01) A61K 38/28 (2006.01) kind of regional protection available): ARIPO (BW, GH, (21) International Application Number: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, PCT/AU2017/050758 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (22) International Filing Date: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 21 July 2017 (21.07.2017) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (25) Filing Language: English KM, ML, MR, NE, SN, TD, TG). (26) Publication Language: English Published: (30) Priority Data: — with international search report (Art. 21(3)) 2016902883 22 July 2016 (22.07.2016) AU — with sequence listing part of description (Rule 5.2(a)) 62/483,118 07 April 2017 (07.04.2017) US (71) Applicants: UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]; 615 Arapreen Drive, Suite 310, Salt Lake City, Utah 84108 (US). THE WAL- TER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 1G Royal Parade, Parkville, Vic- toria 3052 (AU). LA TROBE UNIVERSITY [AU/AU]; Innovation and Commercialisation, 2 Research Avenue, Technology Enterprise Centre, Bundoora, Victoria 3086 (AU). Inventors: MENTING, John Gerbrandt Tasman; 1 (72) Kimberley Way, Bulleen, Victoria 3105 (AU). SMITH, Brian; 6 Kathryn Court, Bundoora, Victoria 3429 (AU). CHOU, Danny Hung-Chieh; 15 North Medical Dri- ve East, Salt Lake City, Utah 84112 (US). SAFAVI- HEMAMI, Helena; 320 N. Margarethe Lane, Salt Lake City, Utah 84108 (US). LAWRENCE, Michael Colin; 154 Woods Street, Newport, Victoria 3015 (AU). BAL- DOMERO, Olivera M.; 1370 E. Bryan Ave, Salt Lake City, Utah 84105 (US). Agent: FB RICE; Level 14, 90 Collins St, Melbourne, Vic- toria 3000 (AU). (74) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) 1-1 Il C:r © 7r ,-1 (54) Title: INSULIN ANALOGS 0 ---- (57) : The present invention relates to insulin analogs, particularly insulin analogs having shortened B chains. The present GC invention also relates to the crystal structure of insulin from the venom of cone snails and to methods of using the crystal and related 0 structural information to screen for and design insulin analogs that interact with or modulate the insulin receptor. The present invention N also relates to therapeutic and prophylactic methods using insulin analogs. C
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016902883A AU2016902883A0 (en) | 2016-07-22 | Insulin Analogs | |
| US201762483118P | 2017-04-07 | 2017-04-07 | |
| PCT/AU2017/050758 WO2018014091A1 (en) | 2016-07-22 | 2017-07-21 | Insulin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900181RA true SG11201900181RA (en) | 2019-02-27 |
Family
ID=65524551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900181RA SG11201900181RA (en) | 2016-07-22 | 2017-07-21 | Insulin analogs |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11248034B2 (en) |
| EP (1) | EP3487876A4 (en) |
| JP (2) | JP7143275B2 (en) |
| KR (2) | KR20230070049A (en) |
| CN (2) | CN116874584A (en) |
| AU (1) | AU2021269301B2 (en) |
| BR (1) | BR112019000991A2 (en) |
| CL (1) | CL2019000159A1 (en) |
| CR (1) | CR20190096A (en) |
| IL (1) | IL264330B2 (en) |
| MA (1) | MA45727A (en) |
| MX (1) | MX2019000829A (en) |
| RU (1) | RU2769476C2 (en) |
| SG (1) | SG11201900181RA (en) |
| ZA (1) | ZA201901095B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769476C2 (en) | 2016-07-22 | 2022-04-01 | Университи Оф Юта Ресёч Фаудэтион | Insulin analogues |
| JP7186400B2 (en) * | 2016-08-30 | 2022-12-09 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Production of seleno-biologics in genomically reencoded organisms |
| WO2023229624A1 (en) * | 2022-05-26 | 2023-11-30 | Transdermal Delivery Solutions Corp. (D.B.A. Hypospray Pharma) | Transdermal insulin formulations and methods of use thereof |
| JP2025505680A (en) | 2022-05-31 | 2025-02-28 | エルジー エナジー ソリューション リミテッド | Polymer solid electrolyte and its manufacturing method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2104305C1 (en) * | 1986-08-29 | 1998-02-10 | Ново Нордиск А.С. | Human insulin analogs, method of their synthesis, injection solution |
| WO2005095443A1 (en) * | 2004-03-31 | 2005-10-13 | Cardio Incorporated | Drug delivery system using peptide modification |
| PL2074141T3 (en) | 2006-09-22 | 2017-02-28 | Novo Nordisk A/S | Protease resistant insulin analogues |
| US7790677B2 (en) * | 2006-12-13 | 2010-09-07 | Elona Biotechnologies | Insulin production methods and pro-insulin constructs |
| WO2009021955A1 (en) * | 2007-08-13 | 2009-02-19 | Novo Nordisk A/S | Rapid acting insulin analogues |
| US9200053B2 (en) * | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
| MY158627A (en) * | 2008-07-31 | 2016-10-31 | Univ Case Western Reserve | Halogen-stabilized insulin |
| EP2376531A1 (en) | 2008-12-09 | 2011-10-19 | Novo Nordisk A/S | Novel insulin analogues |
| US8399407B2 (en) * | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
| AU2012271361B2 (en) | 2011-06-17 | 2017-03-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
| US20160024169A1 (en) * | 2013-03-14 | 2016-01-28 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| CN105228643A (en) * | 2013-03-15 | 2016-01-06 | 卡斯西部储备大学 | Site 2 insulin analog |
| US10227390B2 (en) * | 2013-06-14 | 2019-03-12 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| WO2018014091A1 (en) | 2016-07-22 | 2018-01-25 | University Of Utah Research Foundation | Insulin analogs |
| RU2769476C2 (en) | 2016-07-22 | 2022-04-01 | Университи Оф Юта Ресёч Фаудэтион | Insulin analogues |
| WO2021081335A1 (en) * | 2019-10-24 | 2021-04-29 | University Of Utah Research Foundation | Novel mini-insulin with extended c-terminal a chain |
-
2017
- 2017-07-21 RU RU2019100497A patent/RU2769476C2/en active
- 2017-07-21 MX MX2019000829A patent/MX2019000829A/en unknown
- 2017-07-21 MA MA045727A patent/MA45727A/en unknown
- 2017-07-21 KR KR1020237015079A patent/KR20230070049A/en not_active Ceased
- 2017-07-21 KR KR1020197004760A patent/KR102529353B1/en active Active
- 2017-07-21 CN CN202310855095.4A patent/CN116874584A/en active Pending
- 2017-07-21 US US16/319,450 patent/US11248034B2/en active Active
- 2017-07-21 SG SG11201900181RA patent/SG11201900181RA/en unknown
- 2017-07-21 CR CR20190096A patent/CR20190096A/en unknown
- 2017-07-21 CN CN201780050247.6A patent/CN110072884B/en active Active
- 2017-07-21 IL IL264330A patent/IL264330B2/en unknown
- 2017-07-21 JP JP2019503259A patent/JP7143275B2/en active Active
- 2017-07-21 EP EP17830123.0A patent/EP3487876A4/en active Pending
- 2017-07-21 BR BR112019000991A patent/BR112019000991A2/en unknown
-
2019
- 2019-01-21 CL CL2019000159A patent/CL2019000159A1/en unknown
- 2019-02-20 ZA ZA2019/01095A patent/ZA201901095B/en unknown
-
2021
- 2021-11-16 AU AU2021269301A patent/AU2021269301B2/en active Active
-
2022
- 2022-01-04 US US17/568,698 patent/US12410228B2/en active Active
- 2022-09-14 JP JP2022146483A patent/JP2022191233A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2769476C2 (en) | 2022-04-01 |
| US12410228B2 (en) | 2025-09-09 |
| US20190241640A1 (en) | 2019-08-08 |
| KR102529353B1 (en) | 2023-05-04 |
| KR20190039719A (en) | 2019-04-15 |
| AU2021269301B2 (en) | 2023-12-21 |
| CN116874584A (en) | 2023-10-13 |
| IL264330B1 (en) | 2024-01-01 |
| CL2019000159A1 (en) | 2019-08-16 |
| JP2019534843A (en) | 2019-12-05 |
| JP2022191233A (en) | 2022-12-27 |
| CR20190096A (en) | 2019-09-16 |
| US20220340636A1 (en) | 2022-10-27 |
| EP3487876A4 (en) | 2020-02-19 |
| AU2021269301A1 (en) | 2021-12-09 |
| IL264330A (en) | 2019-03-31 |
| MA45727A (en) | 2019-05-29 |
| ZA201901095B (en) | 2022-04-28 |
| CN110072884B (en) | 2023-07-28 |
| RU2019100497A3 (en) | 2021-05-11 |
| BR112019000991A2 (en) | 2019-07-02 |
| KR20230070049A (en) | 2023-05-19 |
| EP3487876A1 (en) | 2019-05-29 |
| MX2019000829A (en) | 2019-08-29 |
| IL264330B2 (en) | 2024-05-01 |
| CN110072884A (en) | 2019-07-30 |
| JP7143275B2 (en) | 2022-09-28 |
| RU2019100497A (en) | 2020-08-24 |
| NZ750355A (en) | 2023-10-27 |
| US11248034B2 (en) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201808076UA (en) | Facilitating vehicle driving and self-driving | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201900815UA (en) | Expression of pten-long with ocolytic viruses | |
| SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| SG11201900181RA (en) | Insulin analogs | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |